Duchenne Muscular Dystrophy News and Research

RSS
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
Nationwide Children's Hospital pioneers new gene therapy for Duchenne muscular dystrophy

Nationwide Children's Hospital pioneers new gene therapy for Duchenne muscular dystrophy

New porcine model could help develop treatments for Dduchenne muscular dystrophy

New porcine model could help develop treatments for Dduchenne muscular dystrophy

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

Manipulating a signaling protein to slow down muscular dystrophy

Manipulating a signaling protein to slow down muscular dystrophy

Scarring to the collagen framework causes dysfunction in Duchenne muscular dystrophy

Scarring to the collagen framework causes dysfunction in Duchenne muscular dystrophy

Novel molecule may help overcome the devastating symptoms of Duchenne muscular dystrophy

Novel molecule may help overcome the devastating symptoms of Duchenne muscular dystrophy

Rare Diseases Action Plan for England focuses on providing better care and reducing health inequalities

Rare Diseases Action Plan for England focuses on providing better care and reducing health inequalities

Oxford-Harrington Rare Disease Centre hosts virtual event in honor of the upcoming Rare Disease Day

Oxford-Harrington Rare Disease Centre hosts virtual event in honor of the upcoming Rare Disease Day

Using motion capture technology and AI to monitor the progression of movement disorders

Using motion capture technology and AI to monitor the progression of movement disorders

Gene editing could offer a promising solution for treating patients after a heart attack

Gene editing could offer a promising solution for treating patients after a heart attack

Mutations responsible for common inherited heart condition corrected using CRISPR-Cas9 therapy

Mutations responsible for common inherited heart condition corrected using CRISPR-Cas9 therapy

Researchers receive $9 million grant to study how ‘jumping genes’ influence Alzheimer's disease

Researchers receive $9 million grant to study how ‘jumping genes’ influence Alzheimer's disease

New discovery changes the understanding of Duchenne muscular dystrophy

New discovery changes the understanding of Duchenne muscular dystrophy

Experimental drug prolongs survival, improves muscle function in mice severe Duchenne muscular dystrophy

Experimental drug prolongs survival, improves muscle function in mice severe Duchenne muscular dystrophy

Researchers receive $1.2 million Keck Foundation grant to find molecules for targeting the 'undruggable proteome'

Researchers receive $1.2 million Keck Foundation grant to find molecules for targeting the 'undruggable proteome'

Cancer drug helped delay progression of Duchenne muscular dystrophy in mice

Cancer drug helped delay progression of Duchenne muscular dystrophy in mice

Existing cancer drug shows promise for treating patients with muscular dystrophy

Existing cancer drug shows promise for treating patients with muscular dystrophy

U-M researchers reveal how a mutated protein acts as risk factor in Parkinson’s disease

U-M researchers reveal how a mutated protein acts as risk factor in Parkinson’s disease

The promise of RNA medicine is targeted and personalized

The promise of RNA medicine is targeted and personalized

Study supports daily steroid doses for children with Duchenne muscular dystrophy

Study supports daily steroid doses for children with Duchenne muscular dystrophy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.